Talphera, Inc. reported financial results for the second quarter ended June 30, 2026, posting a net loss of $4.3 million, or $0.06 per share, compared to a $3.5 million loss in the prior year period. Combined R&D and SG&A expenses totaled $3.9 million, driven by higher Niyad development costs as enrollment increased. The company holds $17.1 million in cash and investments. Clinically, the NEPHRO CRRT study for nafamostat is 75% enrolled with site realignment complete, targeting year-end completion. Updated KDIGO guidelines now list nafamostat as an acceptable anticoagulant, and revised market research estimates 200,000 annual U.S. CRRT procedures in 2027, a 21% increase over previous projections. Talphera is a specialty pharmaceutical company focused on developing innovative therapies for medically supervised settings.

On June 22, 2026, Talphera, Inc. held its Annual Meeting of Stockholders. Shareholders approved the amendment and restatement of the 2020 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan. Marina Bozilenko, Joseph Todisco, and Mark Wan were elected as Class III directors to serve until the 2029 Annual Meeting. Additionally, stockholders ratified the selection of BPM LLP as the independent registered public accounting firm for the year ending December 31, 2026, and approved executive compensation on an advisory basis. The company operates in the biotechnology industry, focusing on the development of therapeutic products.